ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Technology

Cipla Ltd.

Company Background

Cipla is a major Indian generic drugmaker, competing for second place in the industry in India in terms of the size of its business. It has been doing business in 170 countries and has over 30 production bases. It is a long-established company compared with other Indian leading generic drugmakers. The predecessor of Cipla was founded by K. A. Hamied in 1935, long before India's independence in 1947. It is said that Mahatma Gandhi visited Cipla and asked Hamied to supply medicines that were desperately needed in India at the time. During World War II, Hamied crisscrossed the country to supply medicines that were in short supply due to stagnant imports.

As a trailblazer in India's pharmaceutical industry, Cipla has been busily expanding its business in Africa and other emerging economies. In particular, it is well-known for its low-cost HIV drug. In 2013, it turned a South African company it did business with into a wholly owned subsidiary.

K. A. Hamied's son Yusuf, who earned a doctorate in organic chemistry from the University of Cambridge, took over the company in 1972 and has been serving as the chairman. The founding family owns nearly 40% of the shares in the company.

Business Summary

Cipla Ltd. engages in the manufacture and distribution of healthcare products and bulk drugs. It operates through the following segments: Pharmaceuticals and New Ventures. The Pharmaceuticals segment develops, manufactures, sells and distributes generic or branded generic medicines as well as active pharmaceutical ingredients. The New Ventures segment includes the operations of the two wholly owned subsidiaries, Cipla Health Ltd., a consumer healthcare company and Cipla BioTec Pvt. Ltd, which is into the business of Biosimilars. The company was founded by Khwaja Abdul Hamied in 1935 and is headquartered in Mumbai, India.

Financial Highlights

Mar 2021 INRUSD
Revenue190,622.50M2,567.82M
Gross Profit60,761M818.49M
Operating income32,051.60M431.75M
Income before tax32,900.60M443.19M
Net income24,048.70M323.95M
EBITDA42,057.30M566.54M
Diluted EPS29.780.40
Dividends Per Share50.06
Total Assets251,518.90M3,440.10M
Total liabilities65,587.20M897.05M
Total equity183,265.30M2,506.57M
Operating cash flow36,966.50M497.96M
Currency in INRCurrency in USD

Historical Data

 Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021
Revenue 142,298.10M 150,110.30M 161,887.40M 168,571.40M 190,622.50M
Gross Profit 48,235.70M 52,774.30M 51,888.70M 53,964.60M 60,761M
Operating income 15,212M 17,775.30M 18,901.50M 19,122.50M 32,051.60M
Income before tax 12,221.70M 16,694.60M 20,791.40M 21,781.80M 32,900.60M
Net income 10,063.90M 14,105.30M 15,277M 15,465.20M 24,048.70M
EBITDA 23,926.60M 27,273.40M 29,858.10M 30,095.60M 42,057.30M
Diluted EPS 12.50 17.50 18.93 19.16 29.78
Dividends Per Share 2 3 3 3 5
Total Assets 210,370.70M 228,605.50M 239,633.20M 236,625.60M 251,518.90M
Total liabilities 80,411.30M 82,633.90M 86,090.80M 75,963.70M 65,587.20M
Total equity 125,436.60M 142,291.90M 150,122.80M 157,630M 183,265.30M
Operating cash flow 22,344.50M 13,781.60M 16,047.80M 29,550.80M 36,966.50M
 Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021
Revenue 2,122.04M 2,328.51M 2,314.57M 2,377.39M 2,567.82M
Gross Profit 719.32M 818.63M 741.87M 761.07M 818.49M
Operating income 226.85M 275.73M 270.24M 269.68M 431.75M
Income before tax 182.25M 258.96M 297.26M 307.19M 443.19M
Net income 150.07M 218.80M 218.42M 218.10M 323.95M
EBITDA 356.80M 423.06M 426.89M 424.44M 566.54M
Diluted EPS 0.18 0.27 0.27 0.27 0.40
Dividends Per Share 0.02 0.04 0.04 0.04 0.06
Total Assets 3,239.71M 3,505.05M 3,459.15M 3,127.84M 3,440.10M
Total liabilities 1,238.33M 1,266.96M 1,242.73M 1,004.13M 897.05M
Total equity 1,931.72M 2,181.66M 2,167.05M 2,083.64M 2,506.57M
Operating cash flow 333.21M 213.78M 229.44M 416.76M 497.96M

Valuation Measures

Mar 2021
PER27.33
ROA9.85%
ROE14.10%
Operating margin16.81%
Profit margin12.61%

Key executives

  • Global Chief Executive Officer, MD & Director: Umang Vohra
  • President & Global Chief People Officer: Raju Mistry
  • Global Chief Financial Officer: Kedar Upadhye
  • Global Chief Medical Officer: Jaideep A. Gogtay
  • President-Global Quality & Medical Affairs: Ranjana Pathak

Shareholders

  • HAMIED YUSUF KHWAJA (20.3%)
  • AHMED SOPHIE (5.7%)
  • HAMIED MUSTAFA KHWAJA (4.2%)
  • Life Insurance Corp of India (3.8%)
  • SBI Funds Management Pvt Ltd. (3.6%)
  • Norges Bank Investment Management (2.3%)
  • HAMIED SAMINA VAZIRALLI (2.2%)
  • The Vanguard Group, Inc. (1.9%)
  • BlackRock Fund Advisors (1.5%)
  • ICICI Prudential Asset Management Co. Ltd. (1.5%)

Contact Details

  • Website:http://www.cipla.com
  • Address: Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Mumbai, 400013, India
  • Phone: +91.22.24826000

Related Companies

  • CIpla Ilac TIcaret AS
  • Madison Pharmaceuticals, Inc.
  • Cipla Gulf FZ LLC
  • Cipla Technologies LLC
  • Cipla BioTec South Africa (Pty) Ltd.
  • Cipla Philippines, Inc.
  • Cipla Middle East Pharmaceuticals FZ LLC
  • Medica Pharmaceutical Industries Co. Ltd.
  • Breathe Free Lanka Pvt Ltd.
  • Cipla Medpro Botswana Pty Ltd.
  • Cipla Medpro Distribution Centre Pty Ltd.
  • Cipla Life Sciences Pty Ltd.
  • Cipla Dibcare Pty Ltd.
  • Cape to Cairo Exports Pty Ltd.
  • Cipla Medpro Holdings Pty Ltd.
  • Cipla Malaysia Sdn. Bhd.
  • Cipla Kenya Ltd.
  • Cipla Australia Pty Ltd.
  • Cipla (Mauritius) Ltd.
  • Sitec Labs Ltd.
  • Wanbury Ltd. /4 Brands/
  • AJM Pharma (Pvt) Ltd.
  • Goldencross Pharma Pvt Ltd.
  • Cipla Europe NV
  • Inyanga Trading 386 (Pty) Ltd.
  • Cipla USA, Inc.
  • Meditab Holdings Ltd.
  • Quality Chemicals Ltd.
  • Jay Precision Pharmaceuticals Pvt Ltd.
  • Medispray Laboratories Pvt Ltd.

Competitors

  • Dr. Reddy's Laboratories Ltd.
  • Adcock Ingram Holdings Limited
  • Amneal Pharmaceuticals, Inc. Class A
  • Knight Therapeutics, Inc.
  • Amphastar Pharmaceuticals Inc
  • Iterum Therapeutics plc
  • Spero Therapeutics, Inc.
Last Updated on 22 Oct, 2021

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends October 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more